CME-Certified, Regional Program in collaboration with Moffitt Cancer Center
Saturday, December 7, 2013
8:00 am - 3:00 pm
Tampa Marriott Waterside Hotel and Marina
|Presentations from this program are available through the program schedule tab.|
James J. Mulé, PhD - Moffitt Cancer Center
Vernon K. Sondak, MD - Moffitt Cancer Center
F. Stephen Hodi, Jr., MD - Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACS - Rush University Medical Center
Specifically designed for clinical oncologists and the entire unit of care involved in treating cancer patients with immunotherapy, this CME-certified program provided an understanding of basic immunology principles underlying the clinical application of immunotherapy, provided insights into the indications and clinical management of patients receiving tumor immunotherapy, and discussed emerging drugs and concepts in the tumor immunotherapy field.
Presented by leading authorities in tumor immunology and cancer immunotherapy, this program summarized central themes in tumor immunotherapy and described the latest research advances and focus on currently approved tumor immunotherapy approaches to facilitate understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) management of side effects, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.
Attendees also took advantage of the opportunity for professional networking that promoted collaboration and scientific exchange with experts and clinical oncologists from the surrounding community.
The target audience for this program included practicing clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn increasingly sophisticated principles of tumor immunology and immunotherapy, as well as the role of inflammation in cancer development.
Upon completion of this program, the participant should have been able to:
Jointly-Sponsored by Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer
In collaboration with Moffitt Cancer Center
The Advances in Cancer Immunotherapy series is supported in part by: